RNS14 Mar 2025 07:08
Placing
Stephen West, Roquefort Therapeutics Chairman commented:
"Roquefort Therapeutics continues to operate at a reduced cost base (as announced in May 2024) and today's Placing, along with existing cash, will provide the Company with sufficient headroom for at least the next 12 months, excluding any cash inflows that are generated from the proposed asset sales that we have recently announced. We remain focused on completing the sales of Oncogeni and Lyramid and this fundraise ensures we have sufficient capacity to help execute our strategy."
I’m actually very happy with that, explains the drop.